Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1116 | Control Wiki | 0.53 |
| drug1184 | Couples' Intervention Wiki | 0.50 |
| drug3919 | Sensitivity Intervention Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3920 | Sensitivity and Couples' Intervention Wiki | 0.50 |
| drug4505 | Tremelimumab Wiki | 0.50 |
| drug3977 | Simulation Intervention Wiki | 0.50 |
| drug3040 | PF-07209960 Wiki | 0.50 |
| drug1819 | Growth Mindset Wiki | 0.50 |
| drug1391 | Durvalumab Wiki | 0.35 |
| drug109 | ADCT-301 Wiki | 0.35 |
| drug3124 | Pembrolizumab Wiki | 0.29 |
| drug4690 | Vitamin C Wiki | 0.13 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D002292 | Carcinoma, Renal Cell NIH | 1.00 |
| D002277 | Carcinoma NIH | 0.60 |
| D000077195 | Squamous Cell Carcinoma of Head and Neck NIH | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0030731 | Carcinoma HPO | 0.60 |
| HP:0002894 | Neoplasm of the pancreas HPO | 0.22 |
Navigate: Correlations HPO
There are 4 clinical trials
TRACERx Renal: This is a translational study, which, aims to develop prognostic and predictive biomarkers for patients with renal cell carcinoma (RCC). CAPTURE Sub-study: Covid-19 antiviral response in a pan-tumour immune monitoring study
Description: Outcomes will be quantified using descriptive statistics with the intention of providing hypothesis-generating data for use in future studies.
Measure: To validate ITH index and WGII as stage and grade independent prognostic markers of progression free survival in patients with ccRCC mutation in a gene of interest Time: From trial activation until trial closure approximately 1st September 2023Description: Outcomes will be quantified using descriptive statistics
Measure: CAPTURE Sub-study: Describe the population characteristics between SARS-CoV-2 positive and negative cancer patients Time: From sub-study activation until trial closure approximately 2027RATIONALE: The current global standard of care after nephrectomy for localised RCC therefore remains active monitoring (i.e., observation by clinical and radiological means). 30-40% patients with initially localised RCC develop metastatic disease following nephrectomy. Need for adjuvant therapy is most marked in the high risk population where outcomes are predictably poor. However, the risk of recurrence in patients who are of intermediate risk of recurrence is not insignificant. Unfortunately, despite showing efficacy in advanced RCC, the results in the adjuvant setting, so far, are inconclusive. AIM: RAMPART is a phase III Multi-Arm Multi-Stage randomised controlled platform trial, initiated with three arms. The trial is assessing if durvalumab monotherapy or the combination of durvalumab and tremelimumab can improve Disease Free Survival (DFS) or Overall Survival (OS) compared to the current global standard-of-care (active monitoring). At the start of recruitment, patients with Leibovich scores 3 to 11 will be eligible for randomisation. Accrual of intermediate risk patients (Leibovich scores 3 5) will stop after 3 years or when intermediate risk patients contribute 25% of the total accrual target, whichever is earlier. Recruitment of patients with Leibovich scores 6 to 11 will continue until the accrual target is reached.
Description: Interval from randomisation to first evidence of local recurrence, new primary RCC, distant metastases, or death from any cause, whichever occurs first.
Measure: Disease Free Survival (DFS): Arm C vs A Time: 6.25 yearsDescription: Interval from randomisation to first evidence of local recurrence, new primary RCC, distant metastases, or death from any cause, whichever occurs first.
Measure: Disease Free Survival (DFS): Arm B vs A Time: 10.54 yearsDescription: All-cause mortality, the time from randomisation to death from any cause (including RCC).
Measure: Overall Survival (OS): Arm C vs A (high risk patients only) Time: 13.25 yearsDescription: All-cause mortality, the time from randomisation to death from any cause (including RCC).
Measure: Overall Survival (OS): Arm B vs A (high risk patients only) Time: 20.5 yearsDescription: Interval from randomisation to first evidence of metastases or death from RCC
Measure: Metastasis-free survival (MFS): Arm C vs A Time: 6.25 yearsDescription: Interval from randomisation to first evidence of metastases or death from RCC
Measure: Metastasis-free survival (MFS): Arm B vs A Time: 10.54 yearsDescription: Time from randomisation to death from RCC
Measure: RCC specific survival time: Arm C vs A Time: 13.25 yearsDescription: Time from randomisation to death from RCC
Measure: RCC specific survival time: Arm C vs A Time: 20.5 yearsThis study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.
Description: An AE is defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment.
Measure: Assessment of Dose Limiting Toxicities in Determination of the Maximum Tolerated Dose Limiting toxicities as defined per protocol, as related to ADCT-301 Time: Up to 3 yearsDescription: Adverse events will be graded according to CTAE v4.0 (or more recent). For events not included in the CTCAE criteria, the severity of the AE will be graded on a scale of 1 to 5.
Measure: Number of Adverse Events of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or Above Time: Up to 3 yearsDescription: A SAE is defined as any AE that results in death, is life threatening, requires inpatient hospitalization of prolongation of existing hospitalization (hospitalization for elective procedures or for protocol compliance is not considered an SAE), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical events that do not meet the preceding criteria but based on appropriate medical judgement may jeopardize the patient or may require medical or surgical intervention to prevent any of the outcomes listed above.
Measure: Number of Serious Adverse Events (SAE) Time: Up to 3 yearsDescription: AEs will be graded according to CTCAE v.4.0 (or more recent). For events not included in the CTCAE criteria, the severity of the AE will be graded on a scale of 1 to 5.
Measure: Number of SAEs of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or Above Time: Up to 3 yearsDescription: Overall response rate (ORR) according to the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
Measure: Evaluate the preliminary anti-tumor activity of camidanlumab tesirine Time: Up to 3 yearsDescription: Duration of response (DOR) defined as the time from the first documentation of tumor response to disease progression as per RECIST v1.1
Measure: Evaluate the preliminary anti-tumor activity of camidanlumab tesirine Time: Up to 3 yearsDescription: Progression-free survival (PFS) defined as the time between start of treatment and the first documentation of recurrence or progression as per RECIST v1.1
Measure: Evaluate the preliminary anti-tumor activity of camidanlumab tesirine Time: Up to 3 yearsDescription: Overall survival (OS) defined as the time between the start of treatment and death from any cause
Measure: Evaluate the preliminary anti-tumor activity of camidanlumab tesirine Time: Up to 3 yearsDescription: Noncompartmental analysis of the maximum concentration (Cmax)
Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine total antibody, PBD-conjugated antibody, and unconjugated warhead SG3199 in serum Time: Up to 3 yearsDescription: Noncompartmental analysis of the time to maximum concentration (Tmax)
Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum Time: Up to 3 yearsDescription: Noncompartmental analysis of the area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0 last)
Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum Time: Up to 3 yearsDescription: Noncompartmental analysis of the area under the concentration-time curve from time zero to infinity (AUC0-∞)
Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum Time: Up to 3 yearsDescription: Noncompartmental analysis of the area under the concentration-time curve from time zero to the end of the dosing interval (AUC0-τ)
Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum Time: Up to 3 yearsDescription: Noncompartmental analysis of the accumulation index (AI)
Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum Time: Up to 3 yearsDescription: Noncompartmental analysis of clearance (CL)
Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum Time: Up to 3 yearsDescription: Noncompartmental analysis of volume of distribution (Vd)
Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum Time: Up to 3 yearsDescription: ADA titers if applicable, neutralizing activity to camidanlumab tesirine after treatment with camidanlumab tesirine.
Measure: Number of confirmed positive anti-drug antibody (ADA) responses Time: Up to 3 yearsThis is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic, and potential clinical benefit of PF-07209960, an anti-PD-1 targeting IL-15 fusion protein, in participants with selected locally advanced or metastatic solid tumors for whom no standard therapy is available, or would not be an appropriate option in the opinion of the participant and their treating physician, or participants who have refused standard therapy. The study contains 2 parts, single agent Dose Escalation (Part 1) to determine the recommended dose of PF-07209960, followed by Dose Expansion (Part 2) in selected tumor types at the recommended dose.
Description: DLTs will be evaluated during Cycle 1 (a cycle is 28 days) in Part 1. The number of DLTs will be used to determine the optimal dose
Measure: Number of participants with dose limiting toxicities (DLTs) in Dose Escalation (Part 1) Time: Baseline through 28 days after first dose (Cycle 1)Description: AEs as characterized by type, frequency, severity (graded by CTCAE v.5.0; CRS graded by ASTCT criteria), timing, seriousness, and relationship to study drug
Measure: Number of participants with adverse events (AEs) Time: Baseline through up to 2 yearsDescription: Laboratory abnormalities as characterized by type, frequency, severity (graded by CTCAE v.5.0), and timing
Measure: Number of participants with clinically significant laboratory abnormalities Time: Baseline through up to 2 yearsDescription: Tumor response based on RECIST 1.1
Measure: Objective response rate (ORR) in the Expansion cohorts (Part 2) Time: Baseline through up to 2 years or until disease progressionDescription: Tumor response based on RECIST 1.1
Measure: ORR in Dose Escalation (Part 1) Time: Baseline through up to 2 years or until disease progressionDescription: PK assessment for PF-07209960
Measure: Single dose: Maximal concentration (Cmax) Time: Cycle 1 (each cycle is 28 days), Cycle 2, and Day 1 of each subsequent cycle, and at the End of Treatment visit, up to about 2 yearsDescription: PK assessment for PF-07209960
Measure: Single dose: Time to maximal plasma concentration (Tmax) Time: Cycle 1 (each cycle is 28 days), Cycle 2, and Day 1 of each subsequent cycle, and at the End of Treatment visit, up to about 2 yearsDescription: PK assessment for PF-07209960
Measure: Single dose: Area Under the Curve within one dosing interval (AUCtau) Time: Cycle 1 (each cycle is 28 days), Cycle 2, and Day 1 of each subsequent cycle, and at the End of Treatment visit, up to about 2 yearsDescription: PK assessment for PF-07209960
Measure: Multiple dose: Maximum observed steady state plasma concentration (Cmax,ss) Time: Cycle 1 (each cycle is 28 days), Cycle 2, and Day 1 of each subsequent cycle, and at the End of Treatment visit, up to about 2 yearsDescription: PK assessment for PF-07209960
Measure: Multiple dose: Time to reach Maximum Observed Steady State Plasma Concentration (Tmax,ss) Time: Cycle 1 (each cycle is 28 days), Cycle 2, and Day 1 of each subsequent cycle, and at the End of Treatment visit, up to about 2 yearsDescription: PK assessment for PF-07209960
Measure: Multiple dose: Area Under the curve within one dose interval at steady state (AUCtau,ss) Time: Cycle 1 (each cycle is 28 days), Cycle 2, and Day 1 of each subsequent cycle, and at the End of Treatment visit, up to about 2 yearsDescription: PK assessment for PF-07209960
Measure: Lowest concentration (Ctrough) reached before the next dose is administered Time: Cycle 1 (each cycle is 28 days), Cycle 2, and day 1 of each subsequent cycle, and at the End of Treatment visit, up to about 2 yearsDescription: Incidence, titers, and endogenous IL-15 cross-reactivity of anti-drug antibody and neutralizing antibody against PF-07209960
Measure: Immunogenicity in Expansion Cohorts (Part 2) Time: Cycle 1 (each cycle is 28 days), Cycle 2, and Day 1 of each subsequent cycle, and at the End of Treatment visit, up to about 2 yearsDescription: Effect of PF-07209960 therapy on immune cells in tumor biopsies
Measure: Intratumor T cells in pre-treatment vs. on-treatment tumor biopsy samples in Expansion Cohorts (Part 2) Time: Baseline through start of Cycle 2Description: DCR as assessed using RECIST 1.1
Measure: Disease control rate (DCR) Time: Baseline through up to 2 years or until disease progressionDescription: DOR as assessed using RECIST 1.1
Measure: Duration of response (DOR) Time: Baseline through up to 2 years or until disease progressionDescription: TTP as assessed using RECIST 1.1
Measure: Time to progression (TTP) Time: Baseline through up to 2 years or until disease progressionDescription: PFS as assessed using RECIST 1.1
Measure: Progression free survival (PFS) Time: Baseline through up to 2 years or until disease progressionDescription: Proportion of participants alive
Measure: Overall survival (OS) in the Expansion Cohorts (Part 2) Time: Baseline through up to 2 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports